Impact of methionine synthase reductase polymorphisms in chronic myeloid leukemia patients

Abozer Y. Elderdery; Entesar M. Tebein; Fawaz O. Alenazy; Ahmed M. E. Elkhalifa; Manar G. Shalabi; Anass M. Abbas; Hassan H. Alhassan; Chand B. Davuljigari; Jeremy Mills

doi:10.3390/genes13101729

Impact of methionine synthase reductase polymorphisms in chronic myeloid leukemia patients

Abozer Y. Elderdery, Entesar M. Tebein, Fawaz O. Alenazy, Ahmed M. E. Elkhalifa, Manar G. Shalabi, Anass M. Abbas, Hassan H. Alhassan, Chand B. Davuljigari, Jeremy Mills

Research output: Contribution to journal › Article › peer-review

79 Downloads (Pure)

Abstract

Introduction: Metabolism methionine and of folate play a vital function in cellular methylation reactions, DNA synthesis and epigenetic process. However, polymorphisms of methionine have received much attention in recent medical genetics research.

Objectives: To ascertain whether the common polymorphisms of the MTRR (Methionine Synthase Reductase) A66G gene could play a role in affecting susceptibility to Chronic Myeloid Leukemia (CML) in Sudanese individuals.

Methods: In a case-controlled study, we extracted and analyzed DNA from 200 CML patients and 100 healthy control subjects by the PCR-RFLP method.

Results: We found no significant difference in age or gender between the patient group and controls. The MTRR A66G genotypes were distributed based on the Hardy-Weinberg equilibrium (p > 0.05). The variation of MTRR A66G was less significantly frequent in cases with CML (68.35%) than in controls (87%) (OR = 0.146, 95% CI = 0.162–0.662, p < 0.002). Additionally, AG and GG genotypes and G allele were reducing the CML risk (Odds ratio [OR] = 0.365; 95% CI [0.179–0.746]; p = 0.006; OR = 0.292; 95% CI [0.145–0.590]; p = 0.001 and OR = 0.146; 95% CI [0.162–0.662]; p = 0.002 and OR = 2.0; 95% CI [1.3853–2.817]; respectively, (p = 0.000)).

Conclusions: Our data demonstrated that heterozygous and homozygous mutant genotypes of MTRR polymorphisms were associated with decreased risk of developing CML in the Sudanese population.

Original language	English
Article number	1729
Number of pages	8
Journal	Genes
Volume	13
Issue number	10
DOIs	https://doi.org/10.3390/genes13101729
Publication status	Published - 26 Sept 2022

Keywords

CML
MTRR
folate and genetic polymorphism
Sudanese population

Access to Document

10.3390/genes13101729Licence: CC BY

Impact of Methionine SynthaseFinal published version, 606 KBLicence: CC BY

Cite this

@article{b83ceb0d4d964d669b25f4989c54c4cd,

title = "Impact of methionine synthase reductase polymorphisms in chronic myeloid leukemia patients",

abstract = "Introduction: Metabolism methionine and of folate play a vital function in cellular methylation reactions, DNA synthesis and epigenetic process. However, polymorphisms of methionine have received much attention in recent medical genetics research. Objectives: To ascertain whether the common polymorphisms of the MTRR (Methionine Synthase Reductase) A66G gene could play a role in affecting susceptibility to Chronic Myeloid Leukemia (CML) in Sudanese individuals. Methods: In a case-controlled study, we extracted and analyzed DNA from 200 CML patients and 100 healthy control subjects by the PCR-RFLP method. Results: We found no significant difference in age or gender between the patient group and controls. The MTRR A66G genotypes were distributed based on the Hardy-Weinberg equilibrium (p > 0.05). The variation of MTRR A66G was less significantly frequent in cases with CML (68.35%) than in controls (87%) (OR = 0.146, 95% CI = 0.162–0.662, p < 0.002). Additionally, AG and GG genotypes and G allele were reducing the CML risk (Odds ratio [OR] = 0.365; 95% CI [0.179–0.746]; p = 0.006; OR = 0.292; 95% CI [0.145–0.590]; p = 0.001 and OR = 0.146; 95% CI [0.162–0.662]; p = 0.002 and OR = 2.0; 95% CI [1.3853–2.817]; respectively, (p = 0.000)). Conclusions: Our data demonstrated that heterozygous and homozygous mutant genotypes of MTRR polymorphisms were associated with decreased risk of developing CML in the Sudanese population. ",

keywords = "CML, MTRR, folate and genetic polymorphism, Sudanese population",

author = "Elderdery, {Abozer Y.} and Tebein, {Entesar M.} and Alenazy, {Fawaz O.} and Elkhalifa, {Ahmed M. E.} and Shalabi, {Manar G.} and Abbas, {Anass M.} and Alhassan, {Hassan H.} and Davuljigari, {Chand B.} and Jeremy Mills",

year = "2022",

month = sep,

day = "26",

doi = "10.3390/genes13101729",

language = "English",

volume = "13",

journal = "Genes",

issn = "2073-4425",

publisher = "Multidisciplinary Digital Publishing Institute",

number = "10",

}

TY - JOUR

T1 - Impact of methionine synthase reductase polymorphisms in chronic myeloid leukemia patients

AU - Elderdery, Abozer Y.

AU - Tebein, Entesar M.

AU - Alenazy, Fawaz O.

AU - Elkhalifa, Ahmed M. E.

AU - Shalabi, Manar G.

AU - Abbas, Anass M.

AU - Alhassan, Hassan H.

AU - Davuljigari, Chand B.

AU - Mills, Jeremy

PY - 2022/9/26

Y1 - 2022/9/26

N2 - Introduction: Metabolism methionine and of folate play a vital function in cellular methylation reactions, DNA synthesis and epigenetic process. However, polymorphisms of methionine have received much attention in recent medical genetics research. Objectives: To ascertain whether the common polymorphisms of the MTRR (Methionine Synthase Reductase) A66G gene could play a role in affecting susceptibility to Chronic Myeloid Leukemia (CML) in Sudanese individuals. Methods: In a case-controlled study, we extracted and analyzed DNA from 200 CML patients and 100 healthy control subjects by the PCR-RFLP method. Results: We found no significant difference in age or gender between the patient group and controls. The MTRR A66G genotypes were distributed based on the Hardy-Weinberg equilibrium (p > 0.05). The variation of MTRR A66G was less significantly frequent in cases with CML (68.35%) than in controls (87%) (OR = 0.146, 95% CI = 0.162–0.662, p < 0.002). Additionally, AG and GG genotypes and G allele were reducing the CML risk (Odds ratio [OR] = 0.365; 95% CI [0.179–0.746]; p = 0.006; OR = 0.292; 95% CI [0.145–0.590]; p = 0.001 and OR = 0.146; 95% CI [0.162–0.662]; p = 0.002 and OR = 2.0; 95% CI [1.3853–2.817]; respectively, (p = 0.000)). Conclusions: Our data demonstrated that heterozygous and homozygous mutant genotypes of MTRR polymorphisms were associated with decreased risk of developing CML in the Sudanese population.

AB - Introduction: Metabolism methionine and of folate play a vital function in cellular methylation reactions, DNA synthesis and epigenetic process. However, polymorphisms of methionine have received much attention in recent medical genetics research. Objectives: To ascertain whether the common polymorphisms of the MTRR (Methionine Synthase Reductase) A66G gene could play a role in affecting susceptibility to Chronic Myeloid Leukemia (CML) in Sudanese individuals. Methods: In a case-controlled study, we extracted and analyzed DNA from 200 CML patients and 100 healthy control subjects by the PCR-RFLP method. Results: We found no significant difference in age or gender between the patient group and controls. The MTRR A66G genotypes were distributed based on the Hardy-Weinberg equilibrium (p > 0.05). The variation of MTRR A66G was less significantly frequent in cases with CML (68.35%) than in controls (87%) (OR = 0.146, 95% CI = 0.162–0.662, p < 0.002). Additionally, AG and GG genotypes and G allele were reducing the CML risk (Odds ratio [OR] = 0.365; 95% CI [0.179–0.746]; p = 0.006; OR = 0.292; 95% CI [0.145–0.590]; p = 0.001 and OR = 0.146; 95% CI [0.162–0.662]; p = 0.002 and OR = 2.0; 95% CI [1.3853–2.817]; respectively, (p = 0.000)). Conclusions: Our data demonstrated that heterozygous and homozygous mutant genotypes of MTRR polymorphisms were associated with decreased risk of developing CML in the Sudanese population.

KW - CML

KW - MTRR

KW - folate and genetic polymorphism

KW - Sudanese population

UR - https://www.mdpi.com/2073-4425/13/10/1729

U2 - 10.3390/genes13101729

DO - 10.3390/genes13101729

M3 - Article

SN - 2073-4425

VL - 13

JO - Genes

JF - Genes

IS - 10

M1 - 1729

ER -

Impact of methionine synthase reductase polymorphisms in chronic myeloid leukemia patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this